Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. - Wikidata - awgldk - TriplyDB

Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.

Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.

http://www.wikidata.org/entity/Q36186882

about

Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors Cancer-Associated Myeloid Regulatory Cells Myeloid suppressor cells and immune modulation in lung cancer Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors STAT5 in hematopoietic stem cell biology and transplantation Circulating biomarkers in advanced renal cell carcinoma: clinical applications Improving cancer immunotherapy by targeting the STATe of MDSCs Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected Myeloid-derived cells are key targets of tumor immunotherapy Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics Coordinated regulation of myeloid cells by tumours A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib Phase 1 Dose-Escalation Study with LEC/chTNT-3 and Toceranib Phosphate (Palladia(®)) in Dogs with Spontaneous Malignancies.Novel role for tumor-induced expansion of myeloid-derived cells in cancer cachexia Chemotherapy and tumor microenvironment of pancreatic cancer.Minimal changes in the systemic immune response after nephrectomy of localized renal masses.AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells.Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges.MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3⁺CD56⁺ subset through the co-culturing dendritic cells.Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma.Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma.Intravascular staining for discrimination of vascular and tissue leukocytes.Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth.Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.Expansion of myeloid-derived suppressor cells with arginase activity lasts longer in aged than in young mice after CpG-ODN plus IFA treatment.A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development.Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans Transcriptional regulation of myeloid-derived suppressor cells.

P2860

Q24306212-09EDF3E9-5D0D-44DF-A17F-F86CD607C91F Q26750382-8AFB8EC0-ACE7-407B-B1E1-921AC9EFA0E0 Q26823251-DA9439E4-AC3C-4029-9CEB-5ECB7534985D Q26863418-8FAF09EF-0D2E-4B58-8F84-C5558AB891C5 Q26865532-C02EF675-F12C-4278-81DC-E98A8CCC8C9C Q27022428-353689F1-2724-4F0D-8064-598B972D4152 Q27023770-A6BBEC97-8143-4CA0-8B01-1EEF9F9538B2 Q28066797-11DCF09B-C5F1-487B-87BE-BC6AAF475155 Q28068959-7BC1D977-F0A4-45C4-B017-2F2318FEF92E Q28076760-7CB7848B-2D14-436D-9CD4-4A6A80291DDA Q28080262-7831A668-AF01-4DFB-9FA7-3E0CB6BF7C63 Q28082461-822BED84-0F29-4DF5-8FCC-2F02BC82FE73 Q28084627-22DBD03F-7D3C-48DE-BAB5-BE07A91860B4 Q28388246-138211F2-70F0-47A6-8851-A6A4001C6EC5 Q28393614-841ED91A-64ED-48DA-8AC2-B72FEA7DF473 Q28395157-F65BB516-0EF3-4AC4-995A-C0D2CE865FC7 Q28606538-4EF59A1E-584F-46BF-BCCB-0FE80B8D6210 Q33428144-55550938-41A2-4006-A064-B6F0D866671C Q33834933-3BCA8134-CC2B-493B-A49F-D1DF63804707 Q33876637-1230A8BB-B9F1-4813-8EAD-4A06CC2C8B37 Q34014728-8E59B2C2-D902-472C-BAE6-80C4743BB09F Q34334399-C3CC9728-535D-4841-8529-B8BD70D9CA69 Q34458617-9E5B1CA8-CB9B-4796-8706-95B6FF32CF98 Q34504649-6842341F-0AF3-4E10-B5DC-0F34918B33A4 Q34624383-2DDAE6D2-0684-4145-8388-63323803DB4D Q35028389-B68AD97F-3979-465F-9E50-718440365244 Q35043102-BE638DE6-63CF-47DE-9F48-9497D6AAB54E Q35082018-C0A72721-4A77-4632-BDF1-9428DD2C6ED9 Q35093466-64D58ADB-6B4A-4FFC-B45E-A8680087461E Q35506659-F58A7629-6241-4A1F-9F16-B84B4E8A2B0B Q35546240-D6ABE59F-921B-46ED-B179-6CCA4A57B6B6 Q35596407-18A60B8F-4DB1-42DB-9B00-2C7A6DBF41D4 Q35721553-8A474855-4667-4123-B3F1-19DBB483DA40 Q35740104-8E57CC3A-35FC-496F-B644-45AD1C8FD118 Q35887319-8DB2F696-ACCC-4EE6-BBD4-CCD7E3DD8EA8 Q35898395-07D7B927-74AF-4F27-A000-14E96AA75055 Q35955347-422334A5-81BF-41EB-AF99-01271B361397 Q36107975-8F1F8C86-729B-4A73-85AE-2AB5C3FC8A6B Q36239694-934FF123-44CC-4F4F-84E3-5B86EA7AA0BF Q36322351-C1BD9BB5-9EBA-4387-833F-9E368C605EAB

P2860

Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.

http://www.wikidata.org/entity/Q36186882

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Direct and differential suppre ...... s compartmentally constrained.

@ast

Direct and differential suppre ...... s compartmentally constrained.

@en

type

label

Direct and differential suppre ...... s compartmentally constrained.

@ast

Direct and differential suppre ...... s compartmentally constrained.

@en

prefLabel

Direct and differential suppre ...... s compartmentally constrained.

@ast

Direct and differential suppre ...... s compartmentally constrained.

@en

P1433

Q36186882-DA069DFC-9F08-4A69-A77B-F91A4130F82A

P1476

Q36186882-283CF041-D977-4E7C-A6F3-89935DFBF5AD

P2093

Q36186882-3557C9BC-5765-4E00-B5E3-491307286390

Q36186882-55F321F4-0FBA-4C4C-82CB-93E747F36E09

Q36186882-70EF69E8-CDAC-413D-833F-2DE3E4AE5B1E

Q36186882-80C457EB-4102-4D9B-A15E-C6F9EABAC85E

Q36186882-9844619B-036B-43F6-A2B4-5486D6EC34C2

Q36186882-B9AEFB8F-DBC8-4C99-A203-BE1B9D2569DF

Q36186882-C1C288C5-6365-43B9-9DDF-A15DD06664B2

Q36186882-C74E95F1-02B7-40E0-96BA-C3B6565A8B23

Q36186882-F30547CA-7EA3-4CE1-84C1-C97C05ED12A0

P2860

Q36186882-007E3DFE-A28C-4555-B6DC-B9C616AB2214

Q36186882-0D1BE9B3-78CF-44C4-81A9-1F246353B827

Q36186882-0E445A39-F4AE-4DDF-8DB5-CC3DBC1FBE63

Q36186882-112D1E0A-77BC-4FA0-AAFE-A697F5F26233

Q36186882-11DBDB74-7789-40CF-B06A-E1F5F2AAE105

Q36186882-2389F5B6-BC47-4225-AF69-1D00F92CFA57

Q36186882-27FDE1FA-B881-43CE-BBDF-11562BB84955

Q36186882-2CBFA817-0E26-4921-A431-42E93BC1C5F6

Q36186882-2F486190-0C82-4AF2-8478-E71AC53380DE

Q36186882-2FCD9AF8-B3B0-4A5E-83A9-4B4A22B86BF4

P304

Q36186882-25D5F86E-1057-4391-833D-E2FCA08B3E75

P31

Q36186882-AD666759-C0B4-40E4-B581-E41D7074DD76

P356

Q36186882-BD95049C-17C1-44C6-9A8A-97C98D8C7AEE

P407

Q36186882-0C6957F7-583F-4C83-83B6-CB1A68E292EA

P433

Q36186882-41B6B76C-EB7F-4029-B435-A66A5B55CD97

P478

Q36186882-40DE2693-B88E-4EE0-8459-81A2B8592743

P577

Q36186882-7351EF0F-CCAB-4D8E-81C5-8E1AD4AE7E3B

P698

Q36186882-E8BB35FD-E322-40C7-BB5D-CED524093609

P932

Q36186882-8E218AD2-C464-45FC-A7DA-2218E3D94505

P356

0008-5472.CAN-09-3278

P1433

Cancer Research

P1476

Direct and differential suppre ...... s compartmentally constrained.

@en

P2093

Brian Rini

http://www.w3.org/2001/XMLSchema#string

Geqiang Li

http://www.w3.org/2001/XMLSchema#string

James H Finke

http://www.w3.org/2001/XMLSchema#string

Jennifer S Ko

http://www.w3.org/2001/XMLSchema#string

Joanna Ireland

http://www.w3.org/2001/XMLSchema#string

Kevin D Bunting

http://www.w3.org/2001/XMLSchema#string

Patricia Rayman

http://www.w3.org/2001/XMLSchema#string

Peter A Cohen

http://www.w3.org/2001/XMLSchema#string

Shadi Swaidani

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Myeloid-derived suppressor cells: linking inflammation and cancer

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

Myeloid-derived suppressor cells as regulators of the immune system

Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

The role of myeloid cells in the promotion of tumour angiogenesis

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

Immunosuppressive strategies that are mediated by tumor cells

P304

3526-3536

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-3278

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20406969

http://www.w3.org/2001/XMLSchema#string

P932

3426924

http://www.w3.org/2001/XMLSchema#string